Anti-PD1 therapy alters the immune microenvironment of brain metastases

Neoadjuvant therapy with anti-PD1 therapy remodels the immune microenvironment of brain metastases (BMs), researchers say.

The use of neoadjuvant anti-PD1 therapy has been shown to be effective in controlling BMs of melanoma and non-small cell lung cancer, and has modest efficacy in patients with recurrent glioblastoma (rGBM), according to Dr Lu Sun of the University of California Los Angeles, USA.